TY - JOUR T1 - 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. AU - Kissling,Esther, AU - Valenciano,Marta, AU - Pozo,Francisco, AU - Vilcu,Ana-Maria, AU - Reuss,Annicka, AU - Rizzo,Caterina, AU - Larrauri,Amparo, AU - Horváth,Judit Krisztina, AU - Brytting,Mia, AU - Domegan,Lisa, AU - Korczyńska,Monika, AU - Meijer,Adam, AU - Machado,Ausenda, AU - Ivanciuc,Alina, AU - Višekruna Vučina,Vesna, AU - van der Werf,Sylvie, AU - Schweiger,Brunhilde, AU - Bella,Antonino, AU - Gherasim,Alin, AU - Ferenczi,Annamária, AU - Zakikhany,Katherina, AU - O Donnell,Joan, AU - Paradowska-Stankiewicz,Iwona, AU - Dijkstra,Frederika, AU - Guiomar,Raquel, AU - Lazar,Mihaela, AU - Kurečić Filipović,Sanja, AU - Johansen,Kari, AU - Moren,Alain, AU - ,, Y1 - 2018/03/14/ PY - 2017/10/16/accepted PY - 2017/11/11/pubmed PY - 2019/4/12/medline PY - 2017/11/11/entrez KW - case-control study KW - influenza KW - influenza vaccine KW - multicentre study KW - vaccine effectiveness SP - 423 EP - 437 JF - Influenza and other respiratory viruses JO - Influenza Other Respir Viruses VL - 12 IS - 4 N2 - BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. SN - 1750-2659 UR - https://www.unboundmedicine.com/medline/citation/29125681/2015/16_I_MOVE/I_MOVE+_multicentre_case_control_study_in_Europe:_Moderate_vaccine_effectiveness_estimates_against_influenza_A_H1N1_pdm09_and_low_estimates_against_lineage_mismatched_influenza_B_among_children_ L2 - https://doi.org/10.1111/irv.12520 DB - PRIME DP - Unbound Medicine ER -